New eye drop trial targets chronic dry eye in transplant survivors
NCT ID NCT06852768
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether d-MAPPS eye drops can safely and effectively treat chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell transplant. One adult participant will use the drops or a placebo four times daily for 90 days. Researchers will track symptom changes using dry eye questionnaires and eye scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
d-MAPPS ophthalmic solution (eye drops made from a biological substance)
What this could lead to
If it works, this could point toward a new treatment for chronic dry eye caused by graft-versus-host disease, potentially easing symptoms like grittiness and irritation.
What could go wrong
This is a very early, small trial with only 1 participant, so results may not apply to others. The treatment is compared to placebo, and it may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OGHVD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beach Eye Medical Group
Huntington Beach, California, 92648, United States
-
Beverly Hills Institute of Ophthalmology
Beverly Hills, California, 90210, United States
-
BostonSight
Boston, Massachusetts, 02494, United States
-
Eyewell, LLC.
Boston, Massachusetts, 02215, United States
-
Glenn Eye Center
Lexington, Kentucky, 40511, United States
-
Regenerative Ocular Immunobiologics, LLC.
Palm Harbor, Florida, 34684, United States